Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Would you offer adjuvant radiation therapy for a completely resected, node positive mucoepidermoid carcinoma of the lung?
Related Questions
Would you offer SBRT for a lung lesion adjacent to the heart in a patient receiving bevacizumab?
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
Would you offer SBRT as an alternative to surgery for an atypical carcinoid lung tumor?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?
